NO964008L - Substituerte azetidinonforbindelser som er anvendbare som hypokolesterolemiske midler - Google Patents

Substituerte azetidinonforbindelser som er anvendbare som hypokolesterolemiske midler

Info

Publication number
NO964008L
NO964008L NO964008A NO964008A NO964008L NO 964008 L NO964008 L NO 964008L NO 964008 A NO964008 A NO 964008A NO 964008 A NO964008 A NO 964008A NO 964008 L NO964008 L NO 964008L
Authority
NO
Norway
Prior art keywords
aryl
lower alkyl
substituted
halogen
hydrogen
Prior art date
Application number
NO964008A
Other languages
English (en)
Norwegian (no)
Other versions
NO964008D0 (no
Inventor
Michael P Kirkup
Sundeep Dugar
Bandarpalle B Shankar
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO964008D0 publication Critical patent/NO964008D0/no
Publication of NO964008L publication Critical patent/NO964008L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30—Preparation of optical isomers
    • C07C227/32—Preparation of optical isomers by stereospecific synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO964008A 1994-03-25 1996-09-24 Substituerte azetidinonforbindelser som er anvendbare som hypokolesterolemiske midler NO964008L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21849894A 1994-03-25 1994-03-25
PCT/US1995/003196 WO1995026334A1 (fr) 1994-03-25 1995-03-22 Composes d'azetidinone substituee utiles comme agents hypocholesterolemiques

Publications (2)

Publication Number Publication Date
NO964008D0 NO964008D0 (no) 1996-09-24
NO964008L true NO964008L (no) 1996-11-22

Family

ID=22815366

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964008A NO964008L (no) 1994-03-25 1996-09-24 Substituerte azetidinonforbindelser som er anvendbare som hypokolesterolemiske midler

Country Status (20)

Country Link
US (2) US5627176A (fr)
EP (1) EP0751934B1 (fr)
JP (1) JP3524927B2 (fr)
KR (1) KR100338171B1 (fr)
CN (1) CN1144522A (fr)
AT (1) ATE183738T1 (fr)
AU (1) AU686361B2 (fr)
CA (1) CA2186364C (fr)
CZ (1) CZ281596A3 (fr)
DE (1) DE69511687T2 (fr)
DK (1) DK0751934T3 (fr)
ES (1) ES2135050T3 (fr)
FI (1) FI963817A7 (fr)
GR (1) GR3031105T3 (fr)
HU (1) HU221309B1 (fr)
NO (1) NO964008L (fr)
NZ (1) NZ283528A (fr)
PL (1) PL316431A1 (fr)
SK (1) SK119796A3 (fr)
WO (1) WO1995026334A1 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
EP0877750B1 (fr) 1995-10-31 2002-06-19 Schering Corporation 2-azetidinones substituees par un sucre, utiles comme agents hypocholesterolemiants.
WO1997016424A1 (fr) * 1995-11-02 1997-05-09 Schering Corporation Procede de preparation de 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl ou 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AR023463A1 (es) 1999-04-16 2002-09-04 Schering Corp Uso de compuestos de azetidinona
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
ES2287826T3 (es) * 2000-12-20 2007-12-16 Schering Corp 2-azetidinonas sustituidas con hidroxi utiles como agentes hipocolesterolemicos.
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
DK1355644T3 (da) 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
PL364178A1 (en) * 2001-01-26 2004-12-13 Schering Corporation Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
EP1911462A3 (fr) 2001-01-26 2011-11-30 Schering Corporation Combinaisons comprenant un inhibiteur d'absorption de stérol
DK1373230T3 (da) 2001-03-28 2005-11-07 Schering Corp Enantiselektiv syntese af azetidinon mellemprodukter
JP2005504091A (ja) * 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1859796A3 (fr) * 2001-09-21 2008-07-02 Schering Corporation Treatment de xanthoma avec des dérivés d'azétidines en tant qu'inhibiteurs d'absorption des stérols
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004043457A1 (fr) 2002-11-06 2004-05-27 Schering Corporation Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CA2517571C (fr) * 2003-03-07 2011-07-05 Schering Corporation Azetidinones substituees , procedes pour leur preparation, formulations et utilisations de celles-ci
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1680189A2 (fr) * 2003-11-05 2006-07-19 Schering Corporation Combinaisons de modulateurs lipidiques et d'azetidinones substituees et traitements d'affections vasculaires
EP1918000A2 (fr) 2003-11-05 2008-05-07 Schering Corporation Combinaisons d'agents de modulation lipide et azétidinones substitués et traitements pour conditions vasculaires
AU2004308332B2 (en) * 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
ATE485267T1 (de) 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
JP4590417B2 (ja) * 2004-01-16 2010-12-01 メルク・シャープ・エンド・ドーム・コーポレイション Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法
EP1807070A1 (fr) * 2004-09-29 2007-07-18 Schering Corporation Combinaisons d'azetidinones substituees et d'antagonistes cb1
CN102633730A (zh) 2004-12-03 2012-08-15 先灵公司 作为cb1拮抗剂的取代哌嗪
TW200738676A (en) * 2005-06-20 2007-10-16 Schering Corp Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
JP2009528266A (ja) 2006-01-18 2009-08-06 シェーリング コーポレイション カンナビノイド受容体修飾因子
US7910698B2 (en) * 2006-02-24 2011-03-22 Schering Corporation NPC1L1 orthologues
MX2008011418A (es) * 2006-03-06 2008-09-22 Teva Pharma Composiciones de ezetimibe.
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
US20100125059A1 (en) 2007-03-06 2010-05-20 Teijin Pharma Limited 1-biarylazetidinone derivative
WO2008130616A2 (fr) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines comme modulateurs des récepteurs cb1
US20090047716A1 (en) * 2007-06-07 2009-02-19 Nurit Perlman Reduction processes for the preparation of ezetimibe
CA2692268A1 (fr) * 2007-06-28 2009-01-08 Intervet International B.V. Piperazines a substitution servant d'antagonistes des recepteurs cb1
CA2694264A1 (fr) * 2007-06-28 2009-01-08 Intervet International B.V. Piperazines a substitution servant d'antagonistes des recepteurs cb1
US20090093627A1 (en) * 2007-08-30 2009-04-09 Lorand Szabo Process for preparing intermediates of ezetimibe by microbial reduction
CN101200443B (zh) * 2007-10-17 2011-06-29 中国药科大学 氮杂环丁酮衍生物、其制备方法及含有它们的药物组合
EP2403848A1 (fr) 2009-03-06 2012-01-11 Lipideon Biotechnology AG Compositions pharmaceutiques hypocholestérolémiques
CN101993403B (zh) * 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
ES2802252T3 (es) 2012-05-01 2021-01-18 Althera Life Sciences Llc Formulación de comprimido oral que consiste en la combinación fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares
JP5969958B2 (ja) * 2013-06-27 2016-08-17 国立大学法人お茶の水女子大学 光学活性含フッ素アミノ酸類の製造方法
CN105294426B (zh) * 2014-06-09 2019-05-14 浙江海正药业股份有限公司 氮杂环丁酮化合物制备方法及其中间体
CN104860980B (zh) * 2015-04-23 2018-06-19 上海弈柯莱生物医药科技有限公司 一种用于合成依折麦布的中间体及其制备方法和应用
EP3572075A2 (fr) 2017-01-23 2019-11-27 Dong Wha Pharm. Co., Ltd. Formulation complexe comprenant un inhibiteur de la hmg-coa réductase et du clopidogrel

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
JPH02268144A (ja) * 1989-04-11 1990-11-01 Ube Ind Ltd β―アミノエステルの製造法
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
JP2525125B2 (ja) * 1991-07-23 1996-08-14 シェリング・コーポレーション 血清コレステロ―ル低下薬として有用な置換β−ラクタム化合物およびそれらの製法

Also Published As

Publication number Publication date
PL316431A1 (en) 1997-01-06
CZ281596A3 (en) 1997-05-14
FI963817A0 (fi) 1996-09-25
JPH09510970A (ja) 1997-11-04
WO1995026334A1 (fr) 1995-10-05
NO964008D0 (no) 1996-09-24
DE69511687T2 (de) 2000-03-16
CA2186364A1 (fr) 1995-10-05
FI963817A7 (fi) 1996-09-25
JP3524927B2 (ja) 2004-05-10
DK0751934T3 (da) 1999-12-13
HU221309B1 (en) 2002-09-28
CA2186364C (fr) 2008-12-30
HUT74887A (en) 1997-02-28
NZ283528A (en) 1997-12-19
KR100338171B1 (ko) 2002-11-23
US5627176A (en) 1997-05-06
AU686361B2 (en) 1998-02-05
AU2159695A (en) 1995-10-17
EP0751934A1 (fr) 1997-01-08
ES2135050T3 (es) 1999-10-16
GR3031105T3 (en) 1999-12-31
KR970702246A (ko) 1997-05-13
MX9604030A (es) 1997-09-30
CN1144522A (zh) 1997-03-05
ATE183738T1 (de) 1999-09-15
HU9602616D0 (en) 1996-11-28
EP0751934B1 (fr) 1999-08-25
US5688990A (en) 1997-11-18
SK119796A3 (en) 1997-05-07
DE69511687D1 (de) 1999-09-30

Similar Documents

Publication Publication Date Title
NO964008L (no) Substituerte azetidinonforbindelser som er anvendbare som hypokolesterolemiske midler
TW427974B (en) Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
MX9703577A (es) Compuestos de azetidinona sustituida con azufre, utiles como agentes hipocolesterolemicos.
EG19358A (en) Process for preparing of new n- aryl and n- heteroaryla-mide and urea derivatives as inhibitors of acyl coenzymes a: cholesterol acyl transferase ( A C A T )
EP1362855A4 (fr) Composes de beta-lactame, leur procede de production et agents d'abaissement du taux de cholesterol contenant ces composes
CO5011076A1 (es) Derivados de prolina - d
ATE157870T1 (de) Ophthalmische zusammensetzung enthaltend ein 1,5- benzoxathiepin-derivat zur behandlung von glaukoma
GEP20053505B (en) Diphenyl Ether Compounds Useful in Therapy
HUP0104308A2 (hu) Amidino- és guanidino-azetidinon-származékok, mint triptáz inhibitorok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek
ATE90664T1 (de) 3,5-dihydroxy-6,8-nonadiensaeuren und -derivate als hypocholesterolemische mittel.
DE3888778D1 (de) Polyamin-Derivate als antineoplastische Wirkstoffe.
PH31092A (en) Method of lowering cholesterol
HUT54362A (en) Process for producing cumarin derivatives and pharmaceutical compositions containing them
AU690471B2 (en) Use of 1,4-dihydropyridine derivatives in the prevention and therapy of atherosclerotic degradation of arterial walls
WO1995013264A1 (fr) Derive d'acide hydroxamique et preparation medicamenteuse contenant ledit derive
WO1994003425A3 (fr) Derives de carbostyrile pour le traitement de l'arythmie cardiaque
RU94004910A (ru) Анестезирующее и гемостатическое средство и способ его получения
CA2261271A1 (fr) Derives de dihydrodibenzo(b,e)oxazepine, et compositions medicamenteuses les comportant
GB1334693A (en) Acenaphthene derivatives
RU94032288A (ru) Новые цефалоспориновые производные, способ их получения, фармацевтическая композиция
AU6303296A (en) Process for producing beta-amino-alpha-hydroxycarboxylic acids and derivatives thereof
JPH07278086A (ja) ヒドロキサム酸誘導体およびそれを含有する医薬製剤
ES8503655A1 (es) Un procedimiento para preparar nuevas dihidropiridinas.
JPH0892191A (ja) ヒドロキサム酸誘導体およびそれを含有する医薬製剤
JPH08291127A (ja) ヒドロキサム酸誘導体およびそれを含有する医薬製剤